Mohanraj D, Olson T, Ramakrishnan S
Department of Pharmacology, University of Minnesota, Minneapolis 55455, USA.
Biochem Biophys Res Commun. 1995 Oct 13;215(2):750-6. doi: 10.1006/bbrc.1995.2527.
VEGF is a potent mitogen for vascular endothelial cells in vitro and acts as an angiogenic factor in vivo. VEGF121 differs from the other isoforms in that it lacks the heparin-binding domain. To study the potential differences in biological functions of the VEGF isoforms, we cloned and expressed VEGF121 in a yeast expression system. VEGF121 was secreted from the yeast cells as a homodimer with a molecular weight of 34-36 kDa. By taking advantage of the consecutive histidine residues present at position 11 and 12 in VEGF, a novel method of purification using Nickel affinity chromatography was developed. Since all the isoforms of VEGF have an identical amino terminal end, this method can be used to purify not only VEGF121 but also the other forms of VEGF. The level of expression achieved using this system was as high as 40 mg/L. The recombinant protein was biologically active in stimulating the in vitro proliferation of vascular endothelial cells and positively reacted to an antiserum made against recombinant VEGF165.
血管内皮生长因子(VEGF)在体外是血管内皮细胞的一种强效促有丝分裂原,在体内作为一种血管生成因子发挥作用。VEGF121与其他异构体的不同之处在于它缺乏肝素结合结构域。为了研究VEGF异构体生物学功能的潜在差异,我们在酵母表达系统中克隆并表达了VEGF121。VEGF121以分子量为34 - 36 kDa的同源二聚体形式从酵母细胞中分泌出来。利用VEGF第11和12位存在的连续组氨酸残基,开发了一种使用镍亲和层析的新型纯化方法。由于VEGF的所有异构体都有相同的氨基末端,这种方法不仅可用于纯化VEGF121,还可用于纯化其他形式的VEGF。使用该系统实现的表达水平高达40 mg/L。重组蛋白在刺激血管内皮细胞的体外增殖方面具有生物活性,并与针对重组VEGF165制备的抗血清呈阳性反应。